Skip to search formSkip to main contentSkip to account menu

Eescula

Known as: Rescula 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
The changes in intraocular pressure (IOP) and pupil size (PS) after instillations of 0.15% unoprostone isopropyl (Rescula… 
2004
2004
PURPOSE To investigate the effects of antiglaucoma eyedrops and vehicles on the proliferation of human corneal epithelial cells… 
2001
2001
AIM To investigate the clinical characteristics of docosanoid derivative, isopropyl unoprostone in the treatment of primary open… 
2000
2000
Rescula (0.12% unoprostone isopropyl) is the first docosanoid compound approved for treatment of glaucoma in humans. It is… 
2000
2000
PURPOSE To study the long-term effect of topically applied 0.12% isopropyl unoprostone (unoprostone, Rescula) on microcirculation… 
Highly Cited
1993
Highly Cited
1993
A double-masked comparative clinical study of UF-021 (Rescula), a unique prostaglandin-related compound, was carried out at 18… 
1993
1993
We administered UF-021 isopropyl unoprostone (Rescula) ophthalmic solution, a new prostaglandin-related compound developed as an…